Your browser doesn't support javascript.
loading
Can a new formulation of opiate agonist treatment alter stigma?: Place, time and things in the experience of extended-release buprenorphine depot.
Treloar, Carla; Lancaster, Kari; Gendera, Sandra; Rhodes, Tim; Shahbazi, Jeyran; Byrne, Marianne; Degenhardt, Louisa; Farrell, Michael.
Affiliation
  • Treloar C; Centre for Social Research in Health, UNSW Sydney, Australia. Electronic address: c.treloar@unsw.edu.au.
  • Lancaster K; Centre for Social Research in Health, UNSW Sydney, Australia.
  • Gendera S; Social Policy Research Centre, UNSW Sydney, Australia.
  • Rhodes T; Centre for Social Research in Health, UNSW Sydney, Australia.
  • Shahbazi J; National Drug and Alcohol Research Centre, UNSW Sydney, Australia.
  • Byrne M; National Drug and Alcohol Research Centre, UNSW Sydney, Australia.
  • Degenhardt L; National Drug and Alcohol Research Centre, UNSW Sydney, Australia.
  • Farrell M; National Drug and Alcohol Research Centre, UNSW Sydney, Australia.
Int J Drug Policy ; 107: 103788, 2022 09.
Article in En | MEDLINE | ID: mdl-35816790
INTRODUCTION: Stigma has corrosive effects on all aspects of care and can undermine individual and population health outcomes. Addiction-related stigma has implications for opiate agonist treatment (OAT) and the people who receive, provide and fund it. It is important to understand how stigma is made in OAT and the political purposes that it serves, in order to change the relations of stigma and avoid the reproduction of stigma in the delivery of new treatment formulations, such as extended release buprenorphine (BUP-XR). METHODS: Semi-structured qualitative interviews were conducted at two time points with participants in a prospective single-arm, multicentre, open-label trial of monthly BUP-XR. Thirty-six participants (25 men, 11 women) were interviewed, and of these 32 participated in a second interview to explore their experience of transition from other treatment to BUP-XR. RESULTS: Participants were highly aware of the of the social and material effects of stigma through the negative stereotypes attached to OAT and those who receive it. Participants narrated examples of how stigma governed as a biopower in the relations and practices of OAT provision at numerous levels: structural (such as in public discourse about OAT and the people who receive it, in media, in perceptions about the decisions of investment in medical technologies); organisational (policies about legitimate access to OAT); interpersonal (with health workers) and individual (self-identities). BUP-XR allowed greater freedom and normalcy for clients. The experience of BUP-XR drew attention to the stigmatising potential of time, place and things associated with other OAT requiring daily (or frequent) dosing, accentuating how stigma comes to be materialised as a relational effect of everyday practices. CONCLUSIONS: Receiving BUP-XR allowed participants to avoid some of the everyday biopolitical powers of other forms of OAT and to reshape self-identities. The altering of relations between time, place and things associated with other forms of OAT allowed participants to feel as though they "pass as normal" . However, the negative public discourse and stigma of OAT is a potential threat to BUP-XR to realise its potential for individual and population benefits.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Buprenorphine / Opioid-Related Disorders Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Limits: Female / Humans / Male Language: En Journal: Int J Drug Policy Journal subject: SAUDE PUBLICA / TRANSTORNOS RELACIONADOS COM SUBSTANCIAS Year: 2022 Document type: Article Country of publication: Países Bajos

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Buprenorphine / Opioid-Related Disorders Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Limits: Female / Humans / Male Language: En Journal: Int J Drug Policy Journal subject: SAUDE PUBLICA / TRANSTORNOS RELACIONADOS COM SUBSTANCIAS Year: 2022 Document type: Article Country of publication: Países Bajos